ALREX

LOE Approaching

loteprednol etabonate

NDAOPHTHALMICSUSPENSION/DROPS
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11

Mechanism of Action

CLINICAL PHARMACOLOGY Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen,…

Clinical Trials (5)

NCT03531697Phase 1Completed

Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery

Started Apr 2018
NCT02208297Phase 3Completed

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Started Sep 2014
326 enrolled
InflammationPainCataract
NCT01736527Phase 1Completed

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

Started Jan 2013
12 enrolled
Pharmacokinetics
NCT01695668N/ACompleted

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

Started Aug 2011
75 enrolled
Dry Eyes
NCT01435460Phase 3Completed

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

Started Aug 2010
300 enrolled
Seasonal Allergic Conjunctivitis